275 related articles for article (PubMed ID: 36623798)
21. Macrophage Activation Syndrome Associated With Adult Onset Still's Disease.
Gulzar M; Sabir A; Hamdani MA; Saadia A
J Ayub Med Coll Abbottabad; 2018; 30(2):289-292. PubMed ID: 29938438
[TBL] [Abstract][Full Text] [Related]
22. Co-occurrence of Kikuchi-Fujimoto's disease and Still's disease: case report and review of previously reported cases.
Toribio KA; Kamino H; Hu S; Pomeranz M; Pillinger MH
Clin Rheumatol; 2015 Dec; 34(12):2147-53. PubMed ID: 25098416
[TBL] [Abstract][Full Text] [Related]
23. A Recurrent Case of Adult-onset Still's Disease with Concurrent Acalculous Cholecystitis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis Successfully Treated with Combination Immunosuppressive Therapy.
Arai Y; Ishikawa Y; Abe K; Kato Y; Abe D; Fujiwara M; Kita Y
Intern Med; 2021 Jun; 60(12):1955-1961. PubMed ID: 33518559
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil activation biomarker pentraxin 3 for diagnosis and monitoring of macrophage activation syndrome occurrence in adult-onset Still's disease.
Zhu D; Chen L; Meng J; Wang M; Ma Y; Chen X; Xiao Y; Yi D; Shi H; Sun Y; Liu H; Cheng X; Su Y; Ye J; Chi H; Zhou Z; Yang C; Teng J; Jia J; Hu Q
J Autoimmun; 2024 Apr; 144():103182. PubMed ID: 38460457
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics of macrophage activation syndrome in adult-onset Still's disease.
Gao Q; Yuan Y; Wang Y; Jiang J; Ye Z; Liu T; Jiang Z; Zhao L
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):59-66. PubMed ID: 34251315
[TBL] [Abstract][Full Text] [Related]
26. Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra.
Mylona E; Golfinopoulou S; Samarkos M; Fanourgiakis P; Papadakos V; Skoutelis A
Clin Rheumatol; 2008 May; 27(5):659-61. PubMed ID: 18095015
[TBL] [Abstract][Full Text] [Related]
27. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
[TBL] [Abstract][Full Text] [Related]
28. Risk of macrophage activation syndrome in patients with adult-onset Still's disease with skin involvement: A retrospective cohort study.
Ding Y; Tang S; Li S; Yang C; Liu T; Ying S; Zhu D; Sun C; Chen W; Shi Y; Fang H; Qiao J
J Am Acad Dermatol; 2021 Dec; 85(6):1503-1509. PubMed ID: 33556412
[TBL] [Abstract][Full Text] [Related]
29. The performance of the diagnostic scoring system or criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis for adult-onset Still's disease. A multicentre case-control study in China.
Yao H; Wang Y; Wang Z; Zhao J; Deng X; Zhang Z; Zhao Y; Zhang Y; Shu Q; Jia Y; Li ZG
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):129-134. PubMed ID: 34596030
[TBL] [Abstract][Full Text] [Related]
30. Heliotrope-like manifestation of adult-onset Still disease with macrophage activation syndrome: A case-based review.
Ikeda T; Yokoyama K; Kawakami T
J Dermatol; 2022 Jul; 49(7):736-740. PubMed ID: 35438204
[TBL] [Abstract][Full Text] [Related]
31. Macrophage activation syndrome in neonates born to mothers with adult-onset Still's disease: Perinatal effect of maternal IL-18.
Shimizu M; Kizawa T; Kato R; Suzuki T; Yachie A
Clin Immunol; 2019 Oct; 207():36-39. PubMed ID: 31299380
[TBL] [Abstract][Full Text] [Related]
32. Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.
Wang R; Li T; Ye S; Lv L; Chen S; Wang X; Bao CD; Fu Q
Clin Rheumatol; 2022 Sep; 41(9):2817-2823. PubMed ID: 35590113
[TBL] [Abstract][Full Text] [Related]
33. Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?
Tada Y; Inokuchi S; Maruyama A; Suematsu R; Sakai M; Sadanaga Y; Ono N; Arinobu Y; Koarada S
Rheumatol Int; 2019 Jan; 39(1):97-104. PubMed ID: 30051293
[TBL] [Abstract][Full Text] [Related]
34. Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease.
Ruscitti P; Ursini F; Berardicurti O; Masedu F; Bozzalla Cassione E; Naldi S; Di Cola I; Di Muzio C; De Stefano L; Di Nino E; Navarini L; Vomero M; Bugatti S; Valenti M; Mariani E; Iagnocco A; Montecucco C; Giacomelli R; Cipriani P
Rheumatology (Oxford); 2022 Dec; 62(1):321-329. PubMed ID: 35438139
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review.
Cota-Arce JM; Cota J; De León-Nava MA; Hernández-Cáceres A; Moncayo-Salazar LI; Valle-Alvarado F; Cordero-Moreno VL; Bonfil-Solis KL; Bichara-Figueroa JE; Hernández-Hernández J; Villela L
Semin Arthritis Rheum; 2021 Dec; 51(6):1282-1290. PubMed ID: 34493394
[TBL] [Abstract][Full Text] [Related]
36. A case of bilateral trochleitis in adult-onset Still's disease.
Gutmark R; Eliasieh K; Rivera-Michlig R
Semin Arthritis Rheum; 2014 Apr; 43(5):689-91. PubMed ID: 24176730
[TBL] [Abstract][Full Text] [Related]
37. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
38. Adult-onset Still's disease.
Gerfaud-Valentin M; Jamilloux Y; Iwaz J; Sève P
Autoimmun Rev; 2014 Jul; 13(7):708-22. PubMed ID: 24657513
[TBL] [Abstract][Full Text] [Related]
39. The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature.
Giacomelli R; Sota J; Ruscitti P; Campochiaro C; Colafrancesco S; Dagna L; Iacono D; Iannone F; Lopalco G; Sfriso P; Cantarini L
Clin Exp Rheumatol; 2021; 39(1):187-195. PubMed ID: 32452353
[TBL] [Abstract][Full Text] [Related]
40. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
Bilia S; Giannini D; Rizzelli GML; Tavoni A
Clin Exp Rheumatol; 2020; 38(3):579. PubMed ID: 32456767
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
